Sex-Related Differences in the Risk of SCDe168ĭefibrillators Other than Transvenous ICDse175 11.1. VA and SCD Related to Specific Populationse165 10.1. Interfascicular Reentrant VT (Belhassen Tachycardia)e162 Outflow Tract and Atrioventricular Annular VAe161 VA in the Structurally Normal Hearte160 8.1. Specific Cardiac Channelopathy Syndromese150 Treatment of Recurrent VA in Patients With NICMe134Īrrhythmogenic Right Ventricular Cardiomyopathye135 Primary Prevention of SCD in Patients With NICMe133 Secondary Prevention of SCD in Patients With NICMe132 Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Diseasee128 Primary Prevention of SCD in Patients With Ischemic Heart Diseasee126 Secondary Prevention of SCD in Patients With Ischemic Heart Diseasee123
Ongoing Management of VA and SCD Risk Related to Specific Disease Statese123 7.1.
Surgery and Revascularization Procedures in Patients With Ischemic Heart Diseasee117 5.5.1. VA in Patients With No Apparent Structural Heart Diseasee117 Nonantiarrhythmic Medications and Therapiese115ĭefibrillators for Treatment of VA and SCDe116 Medications With Prominent Sodium Channel Blockadee112 Therapies for Treatment or Prevention of VAe111 5.1. Invasive Cardiac Imaging: Cardiac Catheterization or CT Angiographye110 Genetic Considerations in Arrhythmia Syndromese109 General Evaluation of Patients With Documented or Suspected VAe105 4.1. Population Subgroups and Risk Predictione102 Sustained VT and VF Not Associated With ACSe102 Premature Ventricular Complexes and Nonsustained VTe99
0 kommentar(er)
